• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Effective CMV infection prophylaxis for hematopoietic-cell transplantation

bys25qthea
September 26, 2013
in Chronic Disease, Infectious Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD/CMV

1. Administering CMX001 at 100 mg twice weekly for post-hematopoietic cell transplant patients provides effective prophylaxis against cytomegalovirus (CMV) infection. 

2. The incidence of adverse events, particular acute graft-versus-host disease and diarrhea, appear to be dose-dependent in patients receiving CMX001. 

Evidence Rating Level: 2 (Good)           

Study Rundown: There is currently no effective drug for CMV prophylaxis in patients that receive allogeneic hematopoietic-cell transplantation. CMV seropositivity in these patients portends an increased risk of transplant-related death. Current options for prophylaxis have undesirable nephrotoxic and myelosuppressive effects. In this study, CMX001 – an acyclic nucleoside – is a new drug that successfully provided prophylaxis against CMV infections in post-hematopoietic cell transplant patients. The optimal CMX001 regimen for prophylaxis was determined to be 100 mg twice weekly beginning after transplantation up to 13 weeks post-transplant. Limitations of this study include the unequal distribution of CMV-seropositive and CMV-seronegative patients within each group. Also, CMV serology alone could be a significant predictive factor in determining the success of prophylactic therapy regardless of the drug dose. However, subgroup analysis suggested that CMV-seronegative patients might benefit more from prophylaxis with CMX001 than CMV-seropositive patients. Further studies will be required to assess the long-term safety of this novel drug as well as the optimal prophylactic duration.

Click to read the study, published today in NEJM

RELATED REPORTS

Kidneys from donors with HIV have good safety outcomes in persons with HIV

Kidney Transplantation from Donors with Human Immunodeficiency Virus (HIV) is Non-inferior to Donors Without HIV

#VisualAbstract: Intravenous Levothyroxine Does Not Increase the Number of Heart Transplants in Unstable Brain-Dead Potential Heart Donors

In-Depth [randomized, controlled trial]: This study enrolled 230 patients and randomized them into a placebo group or one of five groups receiving escalating CMX001 doses (40 mg weekly, 100 mg weekly, 200 mg weekly, 100mg twice weekly and 200 mg twice weekly). CMX001 was started between 14-30 days post-transplant and discontinued at 13 weeks post-transplant. The primary endpoint was failure to prevent progression of CMV infection within one week after stopping the study drug. The group that derived the most benefit received CMX001 at 100mg twice weekly. This group had a significantly lower rate of CMV events when compared to placebo (10% v. 37%; risk difference, -27 percentage points; 95%CI, -42 to -12, p=0.002). At this same dose, 4 of 9 (44%) patients who were CMV-seropositive at baseline were positive for CMV DNA during drug administration versus 0 of 41 patients who were CMV-seronegative at baseline. The most common serious adverse events reported at a higher frequency in the CMX001 groups included acute graft-versus-host disease, diarrhea, and pneumonia.

By Jonathan Liu, MD and Adrienne Cheung

More from this author: Combo antifungal therapy most effective treatment for cryptococcal meningitis, Rhinovirus, genes may interact to increase risk of childhood asthma, Functional MRI map for physical pain identified Glutamine and antioxidant supplementation provide no benefit for critically-ill patients New Hepatitis C virus (HCV) treatment effective  

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: CMVstem cellstransplant
Previous Post

Half of C. difficile cases genetically distinct from previous cases

Next Post

Buccal administration of dextrose gel effective for neonatal hypoglycemia

RelatedReports

Pre-exposure prophylaxis (PrEP) effective in preventing HIV infection in high-risk gay men
Infectious Disease

Kidneys from donors with HIV have good safety outcomes in persons with HIV

November 22, 2024
Kidney Transplantation from Donors with Human Immunodeficiency Virus (HIV) is  Non-inferior to Donors Without HIV
StudyGraphics

Kidney Transplantation from Donors with Human Immunodeficiency Virus (HIV) is Non-inferior to Donors Without HIV

October 24, 2024
#VisualAbstract: Intravenous Levothyroxine Does Not Increase the Number of Heart Transplants in Unstable Brain-Dead Potential Heart Donors
StudyGraphics

#VisualAbstract: Intravenous Levothyroxine Does Not Increase the Number of Heart Transplants in Unstable Brain-Dead Potential Heart Donors

December 1, 2023
Compliance-linked incentives increase infant immunizations rates in rural India
Chronic Disease

Live viral vaccines safe for pediatric solid organ transplant recipients

October 17, 2023
Next Post
Buccal administration of dextrose gel effective for neonatal hypoglycemia

Buccal administration of dextrose gel effective for neonatal hypoglycemia

Outer glove exchange and paper surgical gowns decrease bacterial contamination

Hopkins Frailty Score is best predictor of postoperative complications

Computer more accurate than clinical gestalt in predicting ACS

Computer more accurate than clinical gestalt in predicting ACS

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravaginal conjugated oestrogen does not improve continuation rate of ring pessary use
  • Artificial intelligence based clinical decision systems are safe and effective for diabetes management
  • Epic Launchpad propels generative-AI into everyday hospital routines
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.